SourceOne™ Global Partners and Vesifact AG form strategic alliance launching patented application technologies

VesiSorb®, a natural self-assembling colloid delivery system, improves absorption of medical, nutraceutical, and cosmetic ingredients to enhance product performance

CHICAGO, IL – In a move to provide improved absorption of dietary supplement and cosmeceutical ingredients, SourceOne™ Global Partners has announced it has formed a strategic alliance with Vesifact AG, headquartered in Baar, Switzerland. SourceOne will serve as the exclusive worldwide marketing partner whose role is to build and manage a strategic marketing and distribution infrastructure that delivers market access for Vesifact’s products and technologies.

Vesifact is a spin-off from the Swiss Federal Institute of Technology, Zurich (ETH Zurich). It represents a vital link between current research and private industry. Founded in 1987, the Vesifact Technology Transfer Unit was named after the primary research activities of company founder, Dr. Hans Georg Weder, Professor of Pharmaceutical Chemistry and Physical Pharmacy at the ETH Zurich. Marc Weder, a pharmacist and son of Dr. Weder, is also a co-founder of Vesifact and currently serves as the company’s CEO.

The VesiSorb® delivery system, developed by Vesifact, is protected worldwide by multiple U.S. and International granted and pending patents. The first product that Vesifact and SourceOne will introduce using this patented technology is CoQsource™ Bio-Enhanced CoQ₁₀.

With CoQsource, peak absorption of 16.97% was achieved in a clinical study. This represents a significant improvement compared to reported peak absorption values of 2.15%, 3.34%, and 5.44% for CoQ₁₀ in powder, oil dispersion, and lipid solution delivery systems respectively. This compelling data is evidence of the benefits this application technology
delivers. A clinical study comparing CoQsource to three leading “bio-
enhanced” formulas resulted in the VesiSorb delivery system achieving an
AUC of 30.16 µg/ml/10h compared to AUC values of 5.14 µg/ml/10h, 5.72
µg/ml/10h, and 10.65 µg/ml/10h for the three competitive products in the
study.

CoQsource is composed of millions of colloidal droplets that readily
solubilize CoQ_{10} in the GI-tract thereby improving the transport of CoQ_{10}
through the aqueous phase of the GI-lumen to the absorptive epithelium
and hence its bioavailability.

“SourceOne, together with our Swiss partner, Vesifact, is extremely proud
to introduce bio-enhanced ingredients and proprietary formulas containing
CoQ_{10} in both the ubiquinone and ubiquinol forms, as well as
OmegaSmart™ high potency EPA and DHA, Sytrinol®, PMFsource™
Citrus Bioflavonoids, TocoSource® Palm Tocotrienols, and other
proprietary formulas that make up our Cholestrinol™ family of products,”
said Jesse Lopez, President and CEO of SourceOne. “Using this natural
association colloid system, we can now meet the growing demand for
enhanced bioavailability of these unique science-based ingredients and
proprietary formulas taking their absorption and efficacy to the next level,
truly making SourceOne your first choice for heart healthy ingredient
solutions,” said Mr. Lopez.

“Vesifact chose to partner with SourceOne because of their extensive
knowledge of the industry, global perspective and proven marketing
success,” Marc Weder, CEO of Vesifact, said. “Establishing a presence in
a marketplace is not an easy task, but SourceOne has had great success
in bringing their suite of heart healthy ingredients to market. We look
forward to leveraging this partnership as a vehicle to jointly deliver value
with cutting-edge application technology,” added Mr. Weder.

“The need for supplementation with CoQ_{10} is clear and has never been
greater, especially with the dramatic increase in the number of people
taking statin drugs,” Dr. Hans Weder, President of Vesifact, stated. “The
importance of improving absorption and efficacy is also quite evident,” he
said.

Lopez also added, “SourceOne remains committed to delivering peerless
value to the marketplace by following a two-prong approach: a) Superior-
quality branded ingredients that are developed using proprietary
technology, and b) Ingredients that are fully supported by compelling
scientific studies. The investment in building new alliances with leading
R&D companies, like Vesifact, is the foundation upon which we will continue to deliver new, innovative products, and build long-term relationships with our brand marketing and manufacturing customers.”

SourceOne’s stewardship in the alliance will encompass development of strategic marketing plans, leveraging cross-market segment synergies, and other partnership initiatives.

**About SourceOne™ Global Partners**
SourceOne™ Global Partners, headquartered in Chicago, IL, represents a new breed of ingredient supplier, partnering with manufacturing clients to introduce powerfully branded, science-driven products to market with unique product positioning and compelling consumer presence. SourceOne was conceived as a company whose core competency would be to integrate legitimate science with strong trade and consumer branding. They partner with leading suppliers worldwide to source and offer patented ingredients supported by proprietary science as part of turnkey marketing programs that dramatically increases the odds for market success.

**About Vesifact AG**
A vital link between current research and private industry, Vesifact is a spin-off from the Swiss Federal Institute of Technology, Zurich (ETH Zurich). Innovative technology and know-how are developed in Vesifact’s laboratories and upscaled at its production units. They are then applied to commercial products before being transferred to the marketplace. In this way, Vesifact brings the latest know-how to exactly where it is most needed.

Vesifact’s laboratory and R&D facilities meet the ever increasing requirements for top-level research, product development, and innovation. Vesifact produces carrier systems that improve absorption of medical, nutraceutical, and cosmetic ingredients to enhance performance. Vesifact thus fulfils ever-increasing requirements for innovative dosage forms and application technologies, and offers cutting-edge solutions.